Company Profile: Atavistik Bio
Company Overview
Atavistik Bio is a biotechnology company focused on the discovery and development of precision allosteric small molecules. Their mission is to transform therapies for metabolic diseases and cancer using their integrated proprietary drug discovery platform. Based in Massachusetts, the company targets substantial unmet medical needs, notably in oncology and rare genetic diseases. Through its emphasis on precision allosteric therapeutics, Atavistik Bio is positioned at the forefront of biotechnological innovation.
Leadership and Key Personnel
- Bryan E. Stuart: Chief Executive Officer (CEO) and Director on the Board. Stuart has a robust 20-year background in executive roles in the biotechnology sector. His academic credentials include an MBA from Northwestern University's Kellogg School and a Bachelor’s degree from the University of Illinois.
- Marion Dorsch, PhD: President and Chief Scientific Officer, with over 20 years of experience in drug discovery across oncology, inflammation, and rare genetic diseases. Dr. Dorsch brings extensive expertise from her time in the biotechnology and pharmaceutical industries.
- Paul Bruno, PhD: Chief Business Officer, responsible for strategic business initiatives and corporate development. Dr. Bruno previously served as Senior Vice President at Fulcrum Therapeutics, where he played a pivotal role in corporate strategy and negotiations.
- John A. Josey, PhD: Chairman and Venture Partner with The Column Group, with a distinguished career including being the President and CEO of Peloton Therapeutics before its acquisition by Merck. He holds a PhD in organic chemistry and completed postdoctoral work at Caltech.
Strategic Focus and Achievements
Atavistik Bio is pursuing clinical development of novel therapies and has secured $60 million in Series A funding to advance treatments for metabolic diseases and cancer. The company is notable for its work on precision oncology development candidates like ATV-1601, a selective allosteric AKT1 E17K small molecule inhibitor.
Financial and Operational Metrics
Atavistik Bio reported annual revenue of $3.2 million and employs 41 people, reflecting an agile research and development environment fuelled by venture capital firms like The Column Group, Nextech, and Lux Capital.
Competitor Profile
Overview of Competitors
Atavistik Bio contends with competition from several notable firms in the biotechnology sector, including ClexBio, Protera Technologies, Afyren, Be Biopharma, and Scorpion Therapeutics, each with its unique specialization.
- ClexBio: Operating in Oslo, Norway, ClexBio is a preclinical tissue therapeutics company with proprietary technology for bioengineered human blood vessels focused on regenerative medicine.
- Protera Technologies: Although primarily a cloud management service provider, Protera's ventures into protein-based food ingredient development create indirect competition in biotechnological innovation.
- Afyren: A greentech company creating biobased chemicals intended to replace petroleum-based ones, focusing on sustainable chemistry, introduces competition in environmentally conscious biotechnology advancements.
- Be Biopharma: Based in Massachusetts, Be Biopharma is pioneering Engineered B Cell Medicines, emphasizing cellular therapies for diseases like Hemophilia B, thus competing in the precision cellular therapy domain.
- Scorpion Therapeutics: Specializing in precision oncology, Scorpion Therapeutics develops targeted cancer treatments using next-generation chemical proteomics and computational chemistry, posing significant competition in precision medicine.
Atavistik Bio's position in the competitive landscape demands constant surveillance of innovative advancements in both precision therapeutics and sustainable biotech solutions to secure opportunities for collaboration and maintain a competitive edge.
